Meningococcal Meningitis
📧 Sign up to get email alerts when something new happens for Meningococcal Meningitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-08-26Clinical Trial Update: Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months [Phase 1]
A Phase 1 safety study of a meningococcal ACYW135 polysaccharide conjugate vaccine is being conducted in healthy volunteers aged over 3 mont…
-
CLINICAL_TRIALS trial_result · 2016-04-12Clinical Trial Update: Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study
Follow-up results show the persistence of protective antibody titers 12-24 months after NmVac4-A/C/Y/W-135-DT vaccination.
-
CLINICAL_TRIALS trial_result · 2016-01-20Clinical Trial Update: A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years [Phase 3]
This is a Phase 3B open-label study evaluating the safety, tolerability, and immunogenicity of the Novartis Meningococcal B Recombinant Vacc…
-
CLINICAL_TRIALS trial_result · 2015-11-11Clinical Trial Update: Neisseria Meningitidis Burden of Disease Study
GlaxoSmithKline-sponsored burden-of-disease trial focusing on Neisseria meningitidis has completed. The study also concerns infections cause…
-
CLINICAL_TRIALS trial_result · 2015-11-10Clinical Trial Update: Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 [Phase 2, Phase 3]
A completed Phase 2/3 trial evaluated the safety, tolerability, and immunogenicity of a Meningococcal B recombinant vaccine when given as a …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-11-06Clinical Trial Update: Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. [Phase 2]
A Phase 2 clinical trial evaluating the safety and immunogenicity of the Novartis Meningococcal ACWY Conjugate Vaccine in healthy children a…
-
CLINICAL_TRIALS trial_result · 2015-06-25Clinical Trial Update: A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine [Phase 1]
Phase 1 trial evaluating the safety of a freeze-dried Group ACYW135 meningococcal conjugate vaccine.
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216
Follow-up study reports antibody responses to hepatitis B, acellular pertussis toxin, and inactivated poliovirus antigens 1 month after the …
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants [Phase 3]
Pfizer's Phase 3 trial of NeisVac-C in healthy infants evaluated whether concomitant Hepatitis B, inactivated polio and acellular pertussis …
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: NeisVac-C Single Prime Study in Infants [Phase 3]
Pfizer's NeisVac-C single-prime Phase 3 trial in infants has completed.
-
CLINICAL_TRIALS trial_result · 2015-04-23Clinical Trial Update: Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine [Phase 2]
Phase 2 trial evaluating the immunogenicity and safety of a group A, C, Y & W-135 meningococcal polysaccharide diphtheria toxoid conjugate v…
-
CLINICAL_TRIALS trial_result · 2015-04-10Clinical Trial Update: Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants [Phase 3]
Phase 3 trial evaluating immunogenicity, safety, and lot-to-lot consistency of the Novartis Meningococcal B recombinant vaccine when co-admi…
-
CLINICAL_TRIALS trial_result · 2015-03-11Clinical Trial Update: A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years [Phase 3]
Pfizer completed a global Phase 3 safety study of a 120 mcg rLP2086 vaccine in adolescents and young adults (ages 10-25); results were poste…
-
CLINICAL_TRIALS trial_result · 2015-03-09Clinical Trial Update: Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age [Phase 2]
Phase 2 trial update for a bivalent vaccine (Rlp2086) assessing safety, tolerability, and immunogenicity in laboratory workers aged 18-65, c…
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults [Phase 3]
This update reports the completion of a Phase 3b study assessing the safety of the Novartis Meningococcal B Recombinant Vaccine in healthy a…
-
CLINICAL_TRIALS trial_result · 2015-03-04Clinical Trial Update: Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants [Phase 2]
Phase 2 study evaluating safety and immunogenicity of a meningococcal B vaccine in 2-month-old infants. Results were completed and posted in…
-
CLINICAL_TRIALS trial_result · 2015-02-20Clinical Trial Update: Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years [Phase 3]
Phase 3 trial assessing safety and immunogenicity of Novartis Meningococcal B Vaccine (OMV-based) in healthy adolescents aged 11-17, with fo…
-
CLINICAL_TRIALS trial_result · 2015-01-13Clinical Trial Update: Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 [Phase 3]
Phase 3 trial evaluating persistence of antibodies and vaccine response to the meningococcal B recombinant vaccine in 4-year-old children; r…
-
CLINICAL_TRIALS trial_result · 2014-11-26Clinical Trial Update: Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants [Phase 2]
Pfizer conducted a Phase 2 study to evaluate the safety, tolerability, and immunogenicity of its Meningococcal B vaccine in healthy infants;…
-
CLINICAL_TRIALS trial_result · 2014-11-25Clinical Trial Update: Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults [Phase 1]
Pfizer conducted a Phase 1 trial to evaluate the safety and tolerability of the meningococcal B vaccine RLP2086 in healthy adults; results w…
-
CLINICAL_TRIALS trial_result · 2014-11-19Clinical Trial Update: Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines [Phase 2]
Phase 2 trial assessing safety, tolerability, and immunogenicity of a third dose of four formulations of an rMenB + MenACWY meningococcal va…
-
CLINICAL_TRIALS trial_result · 2014-10-02Clinical Trial Update: Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life [Phase 3]
Phase 3 clinical trial evaluating safety and immunogenicity of 2 or 3 doses of a MenACWY conjugate vaccine in healthy infants and the effect…
-
CLINICAL_TRIALS trial_result · 2014-09-19Clinical Trial Update: Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine [Phase 4]
A Phase 4 study reports on durability of antibody responses and B cell kinetics in healthy children after MCC meningococcal vaccination.
-
CLINICAL_TRIALS research · 2014-09-18Clinical Trial Update: Early Waning of Maternal Measles and Meningitis C Antibodies
Clinical trial update reports early waning of maternal antibodies against measles and meningococcal disease (group C), with potential implic…
-
CLINICAL_TRIALS trial_result · 2014-06-18Clinical Trial Update: Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years [Phase 3]
A Phase 3 trial evaluated the immunogenicity and safety of concomitant administration of a Tdap vaccine with a meningococcal ACWY conjugate …